PulseAugur
实时 08:06:04
中文(ZH) 科兴生物补发财报:2025上半年实现销售额1.303亿美元,同比增1.2%

Isomorphic Labs eyes $2B+ funding as Sinovac Biotech posts modest sales gain amid losses

Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, is reportedly in advanced talks to raise over $2 billion in a new funding round. Thrive Capital, which led Isomorphic Labs' initial funding, is expected to spearhead this round, with Alphabet also participating. This follows a period where Sinovac Biotech reported a slight increase in sales but a net loss due to asset impairment charges, while also securing its Nasdaq listing. AI

影响 Accelerates AI's role in drug discovery, potentially leading to faster development of new therapeutics.

排序理由 Significant funding round for an AI-driven drug discovery company.

在 36氪 (36Kr) 阅读 →

AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →

报道来源 [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Sinovac Biotech Resubmits Financial Report: Achieves Sales of $130.3 Million in H1 2025, a 1.2% Increase Year-on-Year

    36氪获悉,科兴生物补发截至2025年6月30日的中期业绩。财报显示,公司上半年实现销售额1.303亿美元,较去年同期的1.287亿美元微增1.2%。然而,受高达6990万美元的资产减值损失影响,出现2170万美元的净亏损。据了解,1月22日,科兴生物公告,公司已正式获得纳斯达克听证委员会批准,将继续维持在纳斯达克全球市场的上市地位,需在5月11日前完成财报报送。